Key Performance
More- Earnings Score: 39
- Momentum Score: 66
- True Yield: N/A
- Financial Health Score: 44
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. granted 44,409 restricted stock units to 15 newly hired non-executive officers on June 16, 2026, as an inducement for employment. The awards were approved by the compensation committee under the Ultragenyx Employment Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years with 25% vesting annually, contingent on continuous employment.
06/19/2026, 4:30 PM • GlobeNewswire
A class action lawsuit has been filed against Ultragenyx Pharmaceutical for allegedly providing misleading statements about setrusumab's efficacy in treating Osteogenesis Imperfecta. The company claimed the drug would reduce fracture rates, but Phase III Orbit and Cosmic studies failed to achieve statistical significance on primary endpoints. Ultragenyx stock plummeted 42.32% on December 29, 2025, following the announcement of study failures. Investors who purchased shares between August 3, 2023, and December 26, 2025, have until April 6, 2026, to apply as lead plaintiffs.
04/06/2026, 10:51 AM • GlobeNewswire
Rosen Law Firm is notifying investors in BlackRock TCP Capital Corp. (TCPC) and other companies about ongoing securities class action lawsuits. The firm is seeking a lead plaintiff by the April 6, 2026 deadline. According to the lawsuit, BlackRock TCP made materially false statements regarding investment valuations, portfolio quality, and net asset value, resulting in investor losses.
04/05/2026, 7:29 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Ultragenyx Pharmaceutical, Kyndryl Holdings, and Vital Farms, urging investors with significant losses to secure legal counsel before upcoming deadlines. The Ultragenyx case alleges the company made misleading statements about setrusumab's effectiveness in treating Osteogenesis Imperfecta, claiming bone density increases did not correlate to reduced fracture rates as promised.
04/05/2026, 6:37 PM • GlobeNewswire
A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging that the company made false and misleading statements regarding its Phase III Orbit study for setrusumab treatment of Osteogenesis Imperfecta. The complaint claims Ultragenyx failed to disclose risks associated with basing optimistic interim analysis benchmarks on Phase II results without proper placebo controls, potentially overstating the drug's efficacy. Investors who purchased securities between August 3, 2023 and December 26, 2025 may be eligible to join the class action.
04/01/2026, 12:00 PM • GlobeNewswire
Ultragenyx Pharmaceutical faces a securities fraud class action lawsuit covering the period from August 3, 2023 to December 26, 2025. The lawsuit was triggered by the company's announcement that Phase 3 studies for setrusumab failed to demonstrate statistically significant reduction in fracture rates, resulting in a 42% stock price decline from $34.19 to $19.72. Investors have until April 6, 2026 to request lead plaintiff status.
03/31/2026, 10:16 PM • GlobeNewswire
Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc alleging securities fraud. The lawsuit stems from Mereo's announcement on December 29, 2025, that its Phase 3 Orbit and Cosmic studies failed to meet primary endpoints, causing the stock to plummet 87.7% to $0.29 per share. Investors have until April 6, 2026, to request Lead Plaintiff status.
03/31/2026, 3:50 PM • GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of Ultragenyx Pharmaceutical investors who purchased securities between August 3, 2023 and December 26, 2025. The complaint alleges that Ultragenyx made false and misleading statements regarding its Phase III Orbit study for the drug setrusumab, failing to disclose risks associated with basing interim analysis benchmarks on Phase II results without placebo controls, which could not rule out that observed improvements were due to standard of care improvements and placebo effects rather than the drug's efficacy.
03/31/2026, 9:00 AM • GlobeNewswire
Rosen Law Firm announces securities class action lawsuits against PomDoctor Ltd. and other companies. PomDoctor investors who purchased shares between October 9, 2025 and December 11, 2025 are encouraged to join the class action before the April 7, 2026 deadline. The lawsuit alleges PomDoctor engaged in fraudulent stock promotion schemes involving social media misinformation, insider share dumping, and misleading public statements about the company's business and prospects.
03/30/2026, 3:53 PM • GlobeNewswire
Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Ultragenyx Pharmaceutical Inc., alleging the company made materially false and misleading statements about its setrusumab drug candidate's ability to reduce fracture rates in osteogenesis imperfecta patients. The lawsuit claims defendants concealed that increased bone density did not correlate with reduced fracture rates, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is April 6, 2026.
03/30/2026, 2:34 PM • GlobeNewswire
Three major securities class action lawsuits have been announced against biopharmaceutical company Ultragenyx Pharmaceutical for allegedly misleading investors about clinical trial results, Driven Brands for misrepresenting financial condition and internal controls, and Super Micro Computer for failing to disclose sales to Chinese companies in violation of export control laws. Investors with substantial losses during the respective class periods are invited to seek lead plaintiff positions.
03/29/2026, 12:40 PM • GlobeNewswire
A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging securities fraud. The complaint claims the company made false statements about setrusumab's effectiveness in treating Osteogenesis Imperfecta and misrepresented Phase III trial results by failing to disclose risks associated with using uncontrolled Phase II data as benchmarks. Investors who purchased shares between August 3, 2023 and December 26, 2025 may be eligible to join the case.
03/29/2026, 12:00 PM • GlobeNewswire
Ultragenyx Pharmaceutical faces a securities class action lawsuit after failing to disclose material information regarding failed Phase 3 clinical trials for setrusumab (UX143) in treating osteogenesis imperfecta. The announcement on December 26, 2025 caused the stock to plummet 42% from $34.19 to $19.72 per share. Investors with losses exceeding $100,000 have until April 6, 2026 to file lead plaintiff applications.
03/25/2026, 9:37 PM • GlobeNewswire
A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging that the company made false and misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta. The complaint claims Ultragenyx misrepresented Phase III trial results by failing to disclose risks associated with using uncontrolled Phase II data as benchmarks. Investors who purchased securities between August 3, 2023 and December 26, 2025 may be eligible to join the case.
03/25/2026, 12:00 PM • GlobeNewswire
Kahn Swick & Foti, LLC announces a class action securities lawsuit against Ultragenyx Pharmaceutical Inc. for alleged securities fraud between August 3, 2023 and December 26, 2025. The lawsuit was triggered by the company's announcement that its Phase 3 Orbit and Cosmic studies for setrusumab failed to demonstrate statistically significant reduction in fracture rates, resulting in a 42% stock price decline from $34.19 to $19.72. Investors have until April 6, 2026 to request lead plaintiff status.
03/24/2026, 10:04 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.